Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Mature Results from a Phase II Trial of Postoperative Concurrent Chemoradiotherapy for Poor Prognosis Cancer of the Esophagus and Gastroesophageal Junction

Mature Results from a Phase II Trial of Postoperative Concurrent Chemoradiotherapy for Poor... ORIGINAL ARTICLE Mature Results from a Phase II Trial of Postoperative Concurrent Chemoradiotherapy for Poor Prognosis Cancer of the Esophagus and Gastroesophageal Junction David J. Adelstein, MD,* Thomas W. Rice, MD,† Lisa A. Rybicki, MS,‡ Jerrold P. Saxton, MD,§ Gregory M. M. Videtic, MD,§ Sudish C. Murthy, MD,† David P. Mason, MD,† Cristina P. Rodriguez, MD,* and Denise I. Ives, RN* espite recent advances in our understanding and treat- Introduction: Mature results are presented from a phase II trial of Dment, esophageal cancer continues to have a very poor postoperative concurrent chemoradiotherapy in patients with poor- 1,2 overall prognosis. Patients with this malignancy typically prognosis cancer of the esophagus and gastroesophageal junction present late in their disease course, often with locoregionally after primary surgical resection. advanced or distant metastatic involvement. As for most solid Methods: Resected patients with a pathologic stage of T3, N1, or tumors, the single most important prognostic factor for sur- M1a were eligible for this trial. Concurrent chemoradiotherapy was vival has been the pathologic disease stage at diagnosis. begun between 6 and 10 weeks after surgery and consisted of Patients presenting with early carcinoma in situ or with T1 radiotherapy (1.8 Gy/d to a planned http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Mature Results from a Phase II Trial of Postoperative Concurrent Chemoradiotherapy for Poor Prognosis Cancer of the Esophagus and Gastroesophageal Junction

Journal of Thoracic Oncology , Volume 4 (10) – Oct 1, 2009

Loading next page...
 
/lp/wolters-kluwer-health/mature-results-from-a-phase-ii-trial-of-postoperative-concurrent-gUszo1OYO2

References (38)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e3181b26f8e
pmid
19668013
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Mature Results from a Phase II Trial of Postoperative Concurrent Chemoradiotherapy for Poor Prognosis Cancer of the Esophagus and Gastroesophageal Junction David J. Adelstein, MD,* Thomas W. Rice, MD,† Lisa A. Rybicki, MS,‡ Jerrold P. Saxton, MD,§ Gregory M. M. Videtic, MD,§ Sudish C. Murthy, MD,† David P. Mason, MD,† Cristina P. Rodriguez, MD,* and Denise I. Ives, RN* espite recent advances in our understanding and treat- Introduction: Mature results are presented from a phase II trial of Dment, esophageal cancer continues to have a very poor postoperative concurrent chemoradiotherapy in patients with poor- 1,2 overall prognosis. Patients with this malignancy typically prognosis cancer of the esophagus and gastroesophageal junction present late in their disease course, often with locoregionally after primary surgical resection. advanced or distant metastatic involvement. As for most solid Methods: Resected patients with a pathologic stage of T3, N1, or tumors, the single most important prognostic factor for sur- M1a were eligible for this trial. Concurrent chemoradiotherapy was vival has been the pathologic disease stage at diagnosis. begun between 6 and 10 weeks after surgery and consisted of Patients presenting with early carcinoma in situ or with T1 radiotherapy (1.8 Gy/d to a planned

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Oct 1, 2009

There are no references for this article.